Author

Maurizio Mangolini

ORCID 0000-0002-0074-7935Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Assay:CITE-seq· 1 Approach:genetic perturbation / CRISPR· 1 Assay:multiome· 1

Frequent Co-Authors

Aubin RamoniD· 2 shared Biao MaiD· 2 shared Emily Souster· 2 shared Matthew GreenigiD· 2 shared Pietro SormanniiD· 2 shared Rajesh KarattiliD· 2 shared Saket SrivastavaiD· 2 shared Shaun P CordobaiD· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Aubin RamonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Engineering armoured in vivo CAR T cells through targeted delivery and transient mRNA gating

Kai Hu, Saket Srivastava, Biao Ma, Yajing Yang, Huimin Wang, Maurizio Mangolini, Jasvinder Kaur Hayre, Emily Souster, Rajesh Karattil, Aubin Ramon, Matthew Greenig, Pietro Sormanni, Shaun P Cordoba, Shimobi C. Onuoha

This paper develops an in vivo CAR T cell platform using lipid nanoparticles and T-trex strategy to enhance safety, efficacy, and tumor control.

bioRxiv · Mar 13, 2026 · PreprintImmunology

Highly potent novel multi-armoured IL13Rα2 CAR-T subverts the immunosuppressive microenvironment of Glioblastoma

Maurizio Mangolini, Saket Srivastava, Emily Souster, Yajing Yang, Huimin Wang, Rajesh Karattil, Liam Schultz, Biao Ma, Diana Pombal, Matthew Greenig, Aubin Ramon, Pietro Sormanni, Shaun P Cordoba, Shimobi C. Onuoha

This paper develops a novel CAR-T cell therapy for glioblastoma that overcomes immunosuppression and improves persistence through a multi-armoured design.

bioRxiv · Jan 10, 2025 · PreprintCancer Biology